# Rapid health evaluation in migrant peoples in transit through Darien, Panama: Protocol for a multi-method qualitative and quantitative study

Authors and affiliations:

Amanda Gabster, PhD*	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá *corresponding author
Monica Jhangimal, MD	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá
Jennifer Toller Erausquin, PhD	University of North Carolina at Greensboro, USA
José Antonio Suárez, MD	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá
Justo Pinzón, MD, MSc	Hospital Universitario Parc Taulí, Sabadell, España
Madeline Baird, MSc	University of Connecticut, USA
Jennifer Katz, BSc	Community Development Network of the Americas, Panamá
Davis Beltran, PhD	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá
Gonzalo Cabezas Talavero,	Community Development Network of the Americas, Panamá
MSc	
Andrés F. Henao-Martínez, MD	University of Colorado Anschutz Medical Campus, USA
Carlos Franco-Paredes, MD	University of Colorado Anschutz Medical Campus, USA and Hospital Infantil
	de Mexico, Federico Gomez, Mexico City, Mexico
Nelson I. Agudelo Higuita., MD	University of Oklahoma Health Sciences Center, USA
Mónica Pachar, MD	Hospital Santo Tomás, Panamá
José Anel González, MD	Hospital Irma De Lourdes Tzanetatos, Panamá
Juan Miguel Pascale, MD, PhD	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá
Migrant Peoples in Transit	Joanne Sánchez, Nathan Gundacker, Candy Nakad, Yamitzel Zaldívar, Fátima
Study Group	Rodriguez, Grace Vistica, Daniel Owen, Thomas Rincón, Eva Gaspard, Florence JN Pierre, Miliza Peralta, Nelsón Cabezón

#### Keywords: migrant peoples, Latin America, health equity, tropical medicine

WC: 3446

## Abstract

### **Background:**

The world is currently unprepared to deal with a the drastic increase in global migration. There is an urgent need to develop programs to protect the well being and health of migrant peoples. Increased population movement is already evident throughout the Americas as exemplified by the rising number of migrant peoples that pass through the Darien neotropical moist broadleaf forest along the border region between Panama and Colombia. The transit of migrant peoples through this area has an increase in the last years. In 2021 an average of 9,400 people entered the region per month compared to 2,000-3,500 people monthly in 2019. Along this trail, there is no access to healthcare, food provision, potable water, or housing. To date, much of what is known about health needs and barriers to healthcare within this population is based on journalistic reports and anecdotes. There is a need for a comprehensive approach to assess the healthcare needs migrant peoples in transit. This study aims to describe demographic characteristics, mental and physical health status and needs, and experiences of host communities, and to identify opportunities to improve healthcare provision to migrant peoples in transit in Panama.

#### Study design and methods:

This multi-method study will include qualitative (n=70) and quantitative (n=520) components. The qualitative component includes interviews with migrant peoples in transit, national and international non-governmental organizations and agencies based in Panama. The quantitative component is a rapid epidemiological study which includes a questionnaire and four clinical screenings: mental health, sexual and reproductive health, general and tropical medicine, and nutrition.

### **Conclusion:**

This study will contribute to a better understanding of the health status and needs of migrant peoples in transit through Darien, Panama. Findings will be used to allocate resources and provide targeted healthcare interventions for migrant peoples in transit through Darien, Panama.

## Introduction

Global migration has risen dramatically in the past twenty years and is considered one of the most significant challenges in recent times. The world is currently unprepared to deal with population movement of this scale, and there is an urgent need to develop programs to protect the well being and health of migrants. Increased population movement is already evident throughout the Americas, where migrants from Africa, Asia, South America, and the Caribbean travel through South and Central America en route to North America. Although other portions of the route may involve travel by air, train, or bus, migrants who arrive in South America headed north must travel on foot through the Darien National Forest along the border region between Panama and Colombia.

The Darien Forest (DF), commonly called the 'Darien Gap,' is a roadless, dense, 106 km long neotropical moist broadleaf forest that interrupts the Panamerican Highway and serves as a natural barrier between Colombia and Panama. The crossing —known to be "the most dangerous and inhospitable" jungle in the world— is a treacherous journey, often taking between seven to fourteen days depending on the route taken, the amount of food carried, and travel group members' abilities (1). Migrants who travel this route have no access to potable water or food and must face deadly river crossings, scorching high temperatures, and poisonous animals. Some indigenous communities situated along the dense forest's outskirts provide a temporary resting place for migrant peoples in transit. Drug traffickers also share the trails, and people who have made the journey have commonly reported human trafficking and violence; moreover, from May to September 2021, 180 cases of rape were reported to Doctors Without Borders (2).

The National Border Police (SENAFRONT) guide migrant peoples who emerge from the Gap to 'Migrant Reception Stations' (MRS), organized by the National Migrant Services. All individuals who enter by foot into Panama, with very few exceptions, pass through these MRS. These posts are part of the international 'controlled flow' of migrant peoples in a coordinated effort between the United States of America (USA) and Panama, where biometric measurements are taken of all

individuals entering the country, as well as to screen for terrorism and keep a document trail of individuals (3, 4). Time spent at the MRS depends on a multitude of factors including the individual's nationality, health needs and demographics; citizens of some countries are allowed to pass quickly, while others may need to wait months for their migration process in Panama. Individuals from South America and the Caribbean (except Haiti and Cuba) are among those who have non-expedited processes and these nationals who arrive in Darien must go through lengthy months-long visa processes before continuing. Citizens from other countries often stay in the Darien MRSs for approximately 8-14 days before being transported to another MRS near the Panama-Costa Rica border, where they will remain for another 5-7 days.

From 2015 to 2021, there has been a steady increase in the number of migrant peoples in transit that pass through the DF at the Colombia-Panama border en route to North America (5-7). Prior to 2020, there were between 2,000-3,000 individuals who crossed into Panama monthly through the DF. This route has been used for centuries to cross between the two countries; however, from 2016 onwards the number of people using this route has increased annually. From January to August 2021, more than 75,000 migrant peoples entered Panama through this route, due to a large number of people unable to cross international borders early in the COVID-19 pandemic (6, 8). Additionally, the perception of the United States' change in immigration policies with the Biden administration has been identified as impacting the number of migrant peoples through these routes (9). Individuals who make this journey come from different countries (Map 1). According to official records from Panama's National Migration Service, over 70% are Haitian citizens, 20% Cuban citizens, and the remaining 10% originate from Sub-Saharan Africa, Asia, and South America (6). Furthermore, from 2018, there has been an increase in children, families, and pregnant women entering Panama on foot through the DF (6, 10). Individuals from outside the continent arrive in South America by land or sea, often arriving in Ecuador or Brazil, beginning their journey by land up to the Panama-Colombia border (5-7).

There is no access to healthcare along the route through the DF and very limited access to needed health services while in the MRSs. During the DF crossing, migrant peoples are exposed to dangerous elements from the days spent in the tropical forest and people encountered during their route. These elements are coupled with increased prevalence of diseases and health

conditions common in their countries of origin prior to beginning their route through Darien. In recent years, Panama's Ministry of Health (MINSA) has provided resources to begin to address the health needs and offer healthcare to migrant peoples in transit at the MRS. However, the COVID-19 pandemic has reoriented healthcare service provision, where healthcare is focused on SARS-CoV-2 diagnosis and quarantine; however other services such as general health, sexual health, mental health, reproductive medicine and fever management have been left aside (11, 12). The Pan-American Health Organization (PAHO) has recommended in their priority actions a need to strengthen surveillance and monitoring of the prevalence of health conditions through: (1) the development of comprehensive profiles of the health status of migrants, and (2) strengthening of national and decentralized health surveillance systems, especially in the border-transit areas that can capture the health status and needs of migrants (13). In accordance with these recommendations, this study protocol is intended to be a rapid assessment of migrant peoples' health status, needs, impact on surrounding communities, and opportunities for improved service provision to this population. Results from the study will inform future healthcare for migrants in transit in Darien and the region.

### Methods

#### Study design and population

This study will use both qualitative and quantitative cross-sectional methods. We will use qualitative research methods to capture the perspectives and experiences of migrant peoples in transit and stakeholders (Table 1). Additionally, we will use qualitative research to learn from the experiences of a variety of stakeholders, including those who provide services, design and allocate resources to programming, and individuals that live in the communities where migrants pass while crossing the DF. Participants within the study's qualitative component include government health and migration personnel, representatives from international organizations working with migrant populations, community members from surrounding host communities, and migrant peoples.

The qualitative component (Component A) will use purposive sampling and undertake semistructured interviews, focus groups and select participant observation to assess health needs and service provision to migrant peoples (Table 2). Qualitative data collection tools (i.e., semi-

structured interview guides for each stakeholder group) will be designed to capture data to describe divergent health priorities and available health services, evaluate patient barriers for accessing health services, and document needed resources for improving healthcare provision according to stakeholder perspectives. Through coding and thematic analysis of interviews, results of the qualitative component will allow our research team to contextualize prevalence data from the quantitative study component. The qualitative component will provide insights from key stakeholder groups, in their own words. Interviews will provide rich descriptions of the migrant experience and health needs of migrants in transit through Darien, as well as challenges to health services provision. We will use this information to prioritize needs and identify targets and strategies for future intervention.

The quantitative component (Component B, Table 1) includes a rapid epidemiological study among migrant peoples in transit. This component will include a self-administered questionnaire, and four clinical screenings: mental health, sexual and reproductive health, general and tropical medicine, and nutrition. Age of inclusion for each subcomponent can be found in Table 2. The self-administered questionnaire includes demographics, migration routes, sexual and reproductive health and behaviours and self-reported health. This questionnaire was developed from existing instruments (some modified for this population) (14-23). For the clinical laboratory components, participants will be asked to provide a mid-stream urine sample and a peripheral blood sample for laboratory point-of-care screenings for the following infections/conditions: hepatitis A,B,C and E, Chagas disease, malaria, dengue, chikungunya, zika, HIV, syphilis and pregnancy (Table 3). Further rapid testing will be applied, according to clinical presentations, as indicated in Table 4. Clinical screening will include a review of the present and past medical history, vital signs, body measurements and a physical examination. On-site treatment (Table 5) and/or referral to primary, secondary or teritiary centers will be organized (supplementary Table A) according to clinical and laboratory findings.

#### Sample size calculations:

To determine the required sample size for (1) participants aged  $\geq 18$  years, and (2) participants aged < 18 years in this cross-sectional, observational study, we used  $n = \frac{Z^2 P(1-P)}{d^2}$  where n is the sample size, Z the confidence statistic, P is expected prevalence and d is the precision (24).

Based on a past survey by the International Migration Organization, we expect 16% of migrant peoples in transit in Panama with gastrointestinal diseases; this prevalence was used for sample size calculation (25). The sampling frame composed of a total population expected to enter the MRS (2500; 20% of those are <18 years). In total, 120 participants <18 years and 160 participants  $\geq$ 18 years will be included. We have a larger planned sample for the questionnaire, as we expect over half of these individuals will consent to filling out the questionnaire but not be willing to participate in the more time-consuming clinical components.

#### Ethical considerations

This study has approval from the *Comité de Bioética de la Investigación del Instituto Conmemorativo Gorgas de Estudios de la Salud* (260/CBI/ICGES/21). Participants 18 years and older will be asked to read a study information sheet and sign the informed consent form. Participants 12-17 years will have their guardian read and sign the guardian information sheet and informed consent form, and the participant will be required to read and sign the informed assent form. Participants <12 years will be required to have a guardian read and sign the informed guardian consent form. Participants will not be offered monetary compensation for their participants will be given educational sheets that cover the syndromes and infections tested for, and these sheets will be posted publicly at the MRSs. The consent forms, assent forms, questionnaire, and educational materials will be available in Spanish, English, French, Haitian Creole, and Portuguese languages.

#### Participant selection

In Component A, we will use purposive sampling. Community leaders will be asked to attend *focus group interviews*, and institutional, national, and organization leaders will share their perspectives through *individual semi-structured interviews*. A group of migrant peoples will also be selected to participate in *individual semi-structured interviews*. Select migrants accessing health services may be accompanied to observe their experiences within available healthcare providers. A total of 70 participant interviews and focus group discussions is anticipated within the qualitative study component as this number is expected to reach saturation in capturing stakeholder perspectives and experiences.

In Component B, participants will be included systematically, where groups of 40-50 individuals arrive at the MRS where the sampling will be undertaken. When lined up to be registered with the Migration Service, small invitation cards will be given to every 1:n person from each stratum. The *n* will be calculated at the start of each day and depends on the number of expected strata to arrive each day, to include between 30-50 participants daily. After the person finalizes the migration registration process, they will be asked to join the study group at the respective study tents. Inclusion and exclusion criteria are dependent on the study component, as outlined in Table 2. As potential participants may be at the MRS for an undetermined amount of time, this study will only include participants who do not have a planned exit from the MRS the day they participate.

## Data capture:

Data capture will differ by study component and methods employed. Component A will include participant observation, semi-structured interviews, and focus groups captured via ethnographic fieldnotes and recorded on a digital recorder. Interviews and focus groups will be conducted in Spanish and, if needed, interviews with migrant persons will be undertaken in English and through real-time interpreters of French, Portuguese, or Haitian Creole. Component B will include a self-administered questionnaire on a tablet using *Kobo Toolbox Software* (Harvard Humanitarian Initiative, Cambridge, MA), and will be stored on the device under the participant's code until wifi is available. Clinical and laboratory information will be inputed into *Kobo Toolbox* with a separate entry for each participant.

### Pharmacological and psychological treatment and referral:

On-site treatment by study subcomponent is found in table 5. If the participant needs to be referred to primary, secondary or teritiary facilities for further care (Supplementary Table A), this will be organized by the study team and the participant will be transported with no cost to them.

### Pharmacological treatment

On-site pharmacological treatment will be given according to the severity of the affectation. A higher level of care will be arranged if needed to on-site or referral to the nearest health center in the town of Meteti or to the secondary and tertiary hospitals, in Chepo and Panama City, respectively. The field clinic where the study is undertaken is rudimentary and will not attend to all needs. Therefore some cases will be referred to health centers and hospitals where a) the condition requires further testing or specialized care, or b) treatment is intravenous or daily injections, as described in Table 5.

#### Psychiatric care and treatment

Following the RHS-15 screening and meeting with the psychiatrist, individuals who would like to participate in group-oriented therapy are welcome to attend language-based sessions. Additionally, at any time, if the participant seems in distress, presents with acute psychosis or self/heteroagression, immediate consultation with an on-site psychiatrist will be done. Treatment protocol is summarized in Table 5 according to syndromic presentations.

#### On-site management of distress:

At any time during the study, if a participant is anxious, depressed, or distressed, the "Distress Protocol" will be activated (Supplementary material B). The "Violence Protocol" will be implemented for individuals who report sexual violence during the qualitative component, questionnaire, or clinical exam (Supplementary material C). These are based on the Ministry of Health procedure for sexual violence, rape, incest, and a previously published protocol for children who report violence that has been used in previous studies in Panama and worldwide (20, 26).

#### Lab and clinical results

The laboratory POC tests and clinical results will be given to every participant in paper format the day they are included in the studies. All results will be explained to the participants at the time results are offered. The results will also be found in a password-protected location on the Gorgas Memorial Institute for Health Studies' webpage. Each participant will have access to a secure portal for one year, which will house their study results and educational sheets. The

portal will be accessible from a phone or computer. The participants' access information and password will be clipped into their passports.

## Data analysis plan

Data analysis will depend on the study component.

For Component A, recordings and fieldnotes will be transcribed; all identifying information will be deleted. The recorded files will be destroyed after the transcription. Transcripts will be coded by MB and AG using *Nvivo* software. Both coders will work independently and codes will be compared, discussed and discrepancies will be resolved. Transcripts will be saved on an encrypted external hard drive. The data will be analyzed with a thematic analysis method and in an essentialist manner, meaning the participant experiences will be revealed. Transcripts will then be coded at a manifestation level to include the main themes. It is also possible that some codes emerge inductively from the data. This hybrid method of analysis from the data has been previously described and demonstrated to be rigorous (27). A thematic map will be constructed, revised, and altered based on team discussions; contradictions and negative cases will be identified and presented.

For Component B, descriptive and analytical methods will be used to describe the findings of the quantitative questionnaire, including sociodemographic factors, sexual and reproductive biography, sexual behaviors, non-consensual sexual relations, self-reported health, family whereabouts, and social wellbeing. In addition, the prevalence of laboratory and clinical diagnoses will be presented for the sample as a whole, as well as for key subgroups, including men, women, adults and young persons. Quantitative questionnaire responses will be used to describe the epidemiology of test positivity and diagnoses. Sociodemographic and behavioral variables that are significantly associated with health outcomes of interest in bivariable analyses will be included in multivariable regression models to estimate strength of adjusted associations and test their significance.

## Discussion

By 2050, the UN estimates that over 1 billion people could be displaced due to climate change alone (28, 29). Many others are leaving their country of origin for work, family, conflict, persecution, and natural disasters (29). This increase in population movement is already evident throughout the Americas, especially in Panama, where migrants from different Caribbean regions, South America, Africa, and Asia, travel through South and Central America en route to North America. Unfortunately, the world and Latin America are not prepared to provide medical care for mass migration.

The Pan-American Health Organization (PAHO) has highlighted a need to strengthen both, health surveillance and the monitoring of existing programs targeted towards migrant peoples in the region (13). This rapid evaluation of health status and service provision among migrant peoples in transit aims to respond to this evidence gap. Through employing a mixed qualitative and quantative approach, the study will investigate the health status and needs among migrant peoples in transit passing through the Darien MRSs. Currently, individuals with acute illness or emergency health conditions, such as pregnancy, may be transferred to nearby MINSA health centers. However, the occurrence of other health conditions, such as anxiety, PTSD, depression, sexually transmitted syndromes and febrile illnesses that are undiagnosed and untreated with potential long term consequences, and mal/under-nutrition, remain largely undetected and ignored and information related to their prevalence remains widely unknown. As the demographics of migrants who opt for this perilous route shift, information related to the health needs of this population and opportunities for strengthening service provision at the MRS is essential to optimize scarce resources targeted towards improving the wellbeing of migrant peoples who pass through this region.

Access to health care is a human right—increasing migrant health and health literacy translate into future social engagement, citizenship, and productivity (30). The overarching goal of this project is to document the health needs of migrant peoples in transit who pass through Panama. To do this, the project will use point of care testing and a comprehensive, easily deployable package of health services. With this information, we will be able to make recommendations on

long-term health interventions with the end goal of reducing the growing health inequalities and social injustices that migrant peoples endure. Strengthening point of care diagnosis and service delivery will be essential to address barriers to quality health care for migrant peoples that frequently have insufficient time to receive provider follow-up and continuity of care. The literature from other contexts of migration indicates that strategies to screen and treat migrant populations for transmissible diseases, including tuberculosis, hepatitis B, hepatitis C, HIV infection, enteric bacteria, and helminths, can be both impactful and cost-effective (31). Addressing these unmet health needs and improving service provision can help alleviate the incredibly marked inequities migrant peoples have experienced and sustained in their journey.

The challenges to deploy and deliver a point of health care for migrants in transit are enormous—facing barriers including discrimination, violence and insufficient access to healthcare (2, 32). Such issues have described a perceived idea of 'deservingness' that categorizes patients, particularly migrant peoples, as more or less deserving of access to quality health care (33). There are few published data on healthcare needs of migrant peoples in transit through Latin America in route to USA. Grey literature from UN and other international NGOs suggest the greatest health needs include treatment of fever, skin problems, diarrhea and prenatal care. The successful implementation of a health screening protocol like this one may become a platform to scale up in different migratory routes in the Americas and in other regions. Furthemore, the successful conduction of this study may provide crucial information to increase awareness and lead to effective targeted healthcare services for migrant peoples in transit.

## Conclusion

The results of the qualitative and quantitative studies answer the PAHO call to contribute to a better understanding of the health status and health needs of migrant peoples in transit through Panama. It will also serve to strengthen national and decentralized health and surveillance systems nationally and regionally. The findings from this study could contribute to overall strategies globally to improve health and wellbeing of migrant peoples in transit.

### Acknowledgments:

We are thankful to the Center for Research and Diagnosis of Emerging and Infectious Diseases, Meteti, Darien of the *Instituto Conmemorativo Gorgas de Estudios de la Salud*, Community Development Network of the Americas, *Servicio Nacional de Fronteras* (SENAFRONT) and *Servicio Nacional de Migración* for their ongoing support. We are additionally thankful to those who have contributed thus far to this project: Acino Swiss Farma, Ann Knudson, and the Oklahoma University's Physicians Pharmacy.

## **Declaration of conflicting interests:**

The authors declare no conflicts of interest.

## Funding

Funding is provided by *Instituto Conmemorativo Gorgas de Estudios de la Salud* (Panama), Community Development Network of the Americas, Acino Swiss Farma (donation), Neglected Tropical Diseases Fund and University of Colorado (donation by Mr. Howard Janzen).

### **Author contributions**

Contributor Role	Role Definition
Conceptualization	AG, MJ, JTE, JAS, JMP
Funding Acquisition	AG, FR, JMP, CFP, NAH
Methodology	AG, MJ, JTE, JAS, JP, MB, JS, JK, CN, DB, CGT
Project Administration	AG, FR
Supervision	JMP
Validation	PM
Visualization	AG
Writing – Original Draft Preparation	AG, MJ, JTE, AHM, JMP
Writing – Review & Editing	AG, MJ, JTE, JAS, JP, MB, JS, JK, CN, DB, YZ, AHM, CFP, NAH, MP, FR, NG, JAG, GV, GCT, JMP

## **ORCID IDs**

Amanda Gabster, PhD*	0000-0002-7712-0444
Monica Jhangimal, MD	0000-0002-2470-055X
Jennifer Toller Erausquin, PhD	0000-0003-4271-6077
José Antonio Suárez, MD	0000-0001-9407-1624
Justo Pinzón, MD, MSc	0000-0002-3084-7793
Madeline Baird, MSc	0000-0003-3490-8722
Jennifer Katz, BSc	0000-0003-2686-1071
Davis Beltran, PhD	0000-0003-3183-3753
Gonzalo Cabezas Talavero, MSc	0000-0003-0401-4621
Andrés F. Henao-Martínez, MD	0000-0001-7363-8652
Carlos Franco-Paredes, MD	0000-0001-8757-643X
Nelson I. Agudelo Higuita., MD	0000-0002-9363-6280
Mónica Pachar, PhD	0000-0003-4400-4209
Nathan Gundacker, MD	0000-0002-1614-5824
José Anel González, MD	0000-0003-4285-2298
Juan Miguel Pascale, MD, PhD	0000-0003-3258-1359

# References

1.UNICEF. The girl who dreamed of pizza in the middle of the world's most dangerous<br/>junglejungleOnline2020[cited2021August].Availablehttps://www.unicef.org/panama/historias/girl-who-dreamed-pizza-middle-worlds-most-<br/>dangerous-jungle.

2. Vyas K. Rapes of U.S.-Bound Migrants Make a Treacherous Route Even More Dangerous. The Wall Street Journal. 2021.

3. Fitzgerald DS. Refuge Beyond Reach How Rich Democracies Repel Asylum Seekers: Oxford University Press; 2019.

4. Gilman D. Barricading the Border: COVID-19 and the Exclusion of Asylum Seekers at the U.S. Southern Border. Frontiers in Human Dynamics. 2020;2(8).

5. TVN Noticias. Alrededor de 17 mil migrantes han transitado por Panamá en lo que va del 2021 2021 [cited 2021 junio]. Available from: <u>https://www.tvn-</u> <u>2.com/nacionales/seguridad/Aproximadamente-mil-migrantes-transitado-</u> Panama 0 5869662986.html.

6. Migración SNd. Estadísticas online2021 [cited 2021 junio]. Available from: <u>https://www.migracion.gob.pa/inicio/estadisticas</u>.

7. International Migration Organization. Seguimiento a la emergencia: Septiembre 2020-Febrero 2021 Online: IOM; 2021 [cited 2021 july]. Available from: <u>https://displacement.iom.int/system/tdf/reports/REPORTE%20DE%20SITUACION-%2318-</u> ERMS-COVID%2019%20%281%29.pdf?file=1&type=node&id=11318.

8. Arcilla Jaramillo O. En 12 años, atravesaron la selva de Darién 188 mil 873 migrantes Online: La Prensa; 2021 [cited 2021 Septiembre]. Available from: <u>https://www.prensa.com/impresa/panorama/en-12-anos-atravesaron-la-selva-de-darien-188-</u> <u>mil-873-migrantes/</u>.

9. Bensman T. A United Nations of Mass Illegal Immigration, Part 1 2021 [updated June 29, 2021; cited 2021 August]. Available from: <u>https://cis.org/Bensman/United-Nations-Mass-Illegal-Immigration-Part-1</u>.

10. UNICEF. Fifteen times more children crossing the Panama jungle towards the USA in the last four years 2021 [cited 2021 july]. Available from: <u>https://www.unicef.org/press-releases/fifteen-times-more-children-crossing-panama-jungle-towards-usa-last-four-years</u>.

11. Pinzón-Espinosa J, Valdés-Florido MJ, Riboldi I, Baysak E, Vieta E. The COVID-19 Pandemic and Mental Health of Refugees, Asylum Seekers, and Migrants. J Affect Disord. 2021;280(Pt A):407-8.

12. Gabster A, Erausquin JT, Michielsen K, Mayaud P, Pascale JM, Pericas C, et al. How did COVID-19 measures impact sexual behaviour and access to HIV/STI services in Panama? Results from a national cross-sectional online survey. Sexually Transmitted Infections. 2021:sextrans-2021-054985.

13. Panamerican Health Organization. Guidance document on migration and health Online: PAHO; 2019 [cited 2021 June]. Available from: <u>https://www.paho.org/en/documents/guidance-document-migration-and-health</u>. 14. Kpokiri EE, Wu D, Srinivas ML, Anderson J, Say L, Kontula O, et al. Development of an international sexual and reproductive health survey instrument: results from a pilot WHO/HRP consultative Delphi process. Sex Transm Infect. 2021.

15. Alasagheirin MH, Clark MK. Skeletal growth, body composition, and metabolic risk among North Sudanese immigrant children. Public Health Nurs. 2018;35(2):91-9.

16. Eurostat. European Health Interview Survey (EHIS wave 3)

Methodological manual online: Publications office of the European Union; 2018 [cited 2021 May]. Available from: <u>https://ec.europa.eu/eurostat/documents/3859598/8762193/KS-02-18-</u>240-EN-N.pdf/5fa53ed4-4367-41c4-b3f5-260ced9ff2f6.

17. Last JM, Adelaide DP. The iceberg: 'completing the clinical picture' in general practice. 1963. Int J Epidemiol. 2013;42(6):1608-13.

18. Rasmussen S, Søndergaard J, Larsen PV, Balasubramaniam K, Elnegaard S, Svendsen RP, et al. The Danish Symptom Cohort: Questionnaire and Feasibility in the Nationwide Study on Symptom Experience and Healthcare-Seeking among 1002000 Individuals. Int J Family Med. 2014;2014:187280.

19. Paik A. The Contexts of Sexual Involvement And Concurrent Sexual Partnerships. Perspectives on Sexual and Reproductive Health, 2010;42(1):33-42.

20. Gabster A, Pascale JM, Cislaghi B, Francis SC, Weiss HA, Martinez A, et al. High prevalence of sexually transmitted infections, and high-risk sexual behaviours among indigenous adolescents of the Comarca Ngäbe-Bugle, Panama. Sexually transmitted diseases. 2019;46(12):780-7.

21. Gabster A, Mohammed DY, Arteaga GB, Castillero O, Mojica N, Dyamond J, et al. Correlates of Sexually Transmitted Infections among Adolescents Attending Public High Schools, Panama, 2015. PloS one. 2016;11(9):e0163391.

22. Condon S, Lieber M, Maillochon F. Feeling Unsafe in Public Places: Understanding Women's Fears. Revue française de sociologie. 2007;48:101-28.

23. Bellón JA, Delgado A, Luna J, P. L. Cuestionario Apoyo Social Funcional de Duke. Med Care. 1988;26:709-23.

24. Khaled Fahim N, Negida A. Sample Size Calculation Guide - Part 1: How to Calculate the Sample Size Based on the Prevalence Rate. Adv J Emerg Med. 2018;2(4):e50.

26. Devries KM, Child JC, Elbourne D, Naker D, Heise L. "I never expected that it would happen, coming to ask me such questions":Ethical aspects of asking children about violence in resource poor settings. Trials. 2015;16:516.

27. Fereday J, Muir-Cochrane E. Demonstrating Rigor Using Thematic Analysis: A Hybrid Approach of Inductive and Deductive Coding and Theme Development. International Journal of Qualitative Methods. 2006;5(1):80-92.

28. The L. Climate migration requires a global response. Lancet. 2020;395(10227):839.


29. UN Migration. World Migration Report 2020: IOM; 2020 [cited 2021 August]. Available from: <u>https://www.un.org/sites/un2.un.org/files/wmr\_2020.pdf</u>.

30. Vissandjée B, Short WE, Bates K. Health and legal literacy for migrants: twinned strands woven in the cloth of social justice and the human right to health care. BMC Int Health Hum Rights. 2017;17(1):10.

31. Panagiotopoulos T. Screening for infectious diseases in newly arrived migrants in Europe: the context matters. Euro Surveill. 2018;23(28).

32. Jackson J. Drugs, migrants and rebels: Life along Darién's Gap. Al Jazeera. 2015 17 may 2015.

33. Willen SS, Selim N, Mendenhall E, Lopez MM, Chowdhury SA, Dilger H. Flourishing: migration and health in social context. BMJ Glob Health. 2021;6(Suppl 1).



Map 1: Countries of origin of migrant peoples in transit, after crossing the Darien Forest, Migrant Reception Stations in Darien, Panama (March 2021).

Table 1: Study com	ponents and	activities to	be undertaken

	Qualitative (Component A)		Q	uantitative Component	В	
	Qualitative data collection	Quantitative questionnaire	Mental Health	Sexual and Reproductive Health	General and Tropical Medicine	Nutrition
Target Population	Community officials, governmental and non- governmental personnel that work with the target population, migrant peoples in transit, people that live in the communities where migrant peoples travel through or live	Migrant peoples in transit	Migrant peoples in transit	Migrant peoples in transit	Migrant peoples in transit	Migrant peoples in transit

Activities	Semi-structured interviews, focus groups and participant observation	Self-administered quantitative questionnaire	Clinical evaluation and screening	Clinical evaluation and screening	Clinical evaluation and screening	Clinical evaluation and screening
------------	--	--	--------------------------------------	--------------------------------------	--------------------------------------	--------------------------------------

# Table 2: Inclusion and exclusion criteria for the study

	Inclusion criteria	Exclusion criterion
Qualitative Study	<ol> <li>Aged &gt;17 years</li> <li>Speak and write at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese</li> </ol>	
Quantitative Questionnaire	<ol> <li>Aged &gt;17 years</li> <li>Speak and write at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese</li> </ol>	
Mental health	<ol> <li>Aged &gt;12 years</li> <li>Speak and write at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese</li> </ol>	Have a planned exit from an MRS the same day the
Sexual and Reproductive Health	<ol> <li>Aged &gt;12 years</li> <li>Speak and write at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese</li> </ol>	study team has reached the person
General and Tropical Medicine	1. Speak and write at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese	
Nutrition	<ol> <li>Speak and write, or have a guardian if under 12 that speaks and writes at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese</li> </ol>	

	Activity	Target population	Site	Primary outcomes
	Focus groups	Host communities	Host communities	Effects of migrant presence on communities, health priorities, and needs.
Qualitative	Semi- structured interviews and participant observation	Migrant peoples in transit	MRS	Migration experience, barriers to health access and existing programs, health needs
Component	Semi- structured interviews and participant observation	Public institution and non-profit national/international organization leaders who work with migrant populations in transit	MRS, health centers, institutional and organization offices	Health services available, barriers to access, needs of institutions and organizations
Quantitative Component	Self- administered questionnaire	Migrant peoples in transit	MRS	<ul> <li>Sociodemographic and journey information</li> <li>Human smuggling and trafficking</li> <li>Education and employment</li> <li>Self-rated health status</li> <li>Sexual biography and sexual experience</li> <li>Female genital cutting (for some countries)</li> <li>Pregnancy and fertility</li> <li>Self-reported STI/HIV current and past</li> <li>Non-consensual sex</li> <li>Whereabouts of family members and communication with family</li> <li>Felt social support</li> </ul>
	Mental health	Migrant peoples in transit	MRS	<ul> <li>Use of Refugee Health Screener to do an initial screen of PTSD, depression, anxiety, and somatization.</li> <li>MINI Neuropsychiatric International Interview: Diagnosis by DSM-5 and ICD-10 criteria</li> <li>EUROHIS Quality of life interview: subjective quality of life</li> </ul>

# Table 3: Study activity, target population, and primary outcomes

Sexual and reproductive health	Migrant peoples in transit	MRS	<ul> <li>Screening for vaginal and urethral discharge disease</li> <li>Screening for genital ulcer disease</li> <li>Urine dipstick test (leukocyte esterase and nitrite)</li> <li>HIV rapid test (4<sup>th</sup> generation)</li> <li>Syphilis rapid test, RPR titer confirmatory</li> </ul>
General and tropical medicine	Migrant peoples in transit	MRS	<ul> <li>Rapid point of care tests for:         <ul> <li>HAV</li> <li>HBV</li> <li>HCV</li> <li>HEV</li> <li>Chagas</li> <li>Malaria</li> <li>Dengue</li> <li>Chikungunya</li> <li>Zika</li> <li>Pregnancy</li> <li>Further screening based on clinical presentation (Table 4)</li> </ul> </li> <li>Clinical screening:         <ul> <li>Review of present and past medical history</li> <li>Vital signs: Blood pressure, heart rate, respiratory frequency, temperature, blood oxygen saturation</li> <li>Physical examination based on systems: neurological, cardiovascular, respiratory, gastrointestinal, hepatosplenic, skin, and genitourinary</li> </ul> </li> </ul>
Nutrition	Migrant peoples in transit	MRS	<ul> <li>Screening for malnutrition and undernourishment         <ul> <li>Height-weight</li> <li>Body Mass Index (BMI)</li> <li>MUAC</li> <li>Marasmus and Kwashiorkor screening</li> <li>MUST</li> <li>Skinfold test</li> <li>OMS growth charts</li> </ul> </li> </ul>

Test	Clinical Criteria for inclusion
COVID-19 (Antigen or PCR)	Fever or clinical suspicion
Crypto-Giardia-Entamoeba (antigen)	Diarrhea
Cytomegalovirus (antibody)	HIV positive, pregnant women with clinical suspicion
Yellow Fever (PCR)	Fever or clinical suspicion
Amsel Criteria	Vaginal secretion and suspicion of candidiasis
Trypanosoma cruzi detection (Blood smear)	Chagas positive test result, presence of acute symptoms, and suspicion based on country of origin
Leishmaniasis (Tissue Giemsa Stain)	Suggestive ulcer and clinical suspicion
Mycobacterium leprae (Ziehl-Nielsen Stain or	Clinical suspicion of hypochromic anesthetic
Fite-Faraco Stain)	lesion or nodule
Leptospira (serum /IgGIgM antibody)	Fever or clinical suspicion
Malaria- (thick blood smear)	Clinical suspicion and based on country of origin (if endemic)
Rota/adenovirus (Stool antigen)	Pediatric age with diarrhea or gastroenteritis, in adults: fever and symptomatic respiratory
Measles (antibody)	Fever, malaise rash, cough, coryza, conjunctivitis, enanthem, and morbilliform exanthem
TORCH: Toxoplasmosis, Rubeola, CMV, HSV 1 and 2 (antibody)	Pregnant and in 1-month-old babies
Toxoplasmosis (antibody IgG)	HIV positive, pregnancy, and/or clinical
	suspicion
Tuberculosis (Sputum Bacilloscopic)	Fever, cough, nocturnal sweat, HIV +
Typhus / Para-typhus (Stool antigen)	Fever and clinical suspicion

Table 4: Further test based on clinical criteria for inclusion

# Table 5: On-site treatment by study subcomponent

Study sub-	Treatment Given On-Site for Diagnosed Etiology or Based on Clinical and Syndromic
component	Suspician
Mental Health	
	Distress, psychosis, and/or risk of self or hetero-aggressive outburst: Management with verbal containment and, if needed, pharmacologic management with 5mg of diazepam, repeated up to two times; if not, olanzapine 5mg PO or haloperidol 5mg IM.
Sexual and Reproductive Health	
пеани	1. Genital Herpes simplex: Acyclovir 400mg PO TID for seven days.
	<ol> <li>Gentral Helpes simplex. Acyclovit 400ing PO TiD for seven days.</li> <li>Recurrent genital Herpes Simplex: 800mg PO TID for 2 days or 400mg PO TID for 5 days.</li> <li>Syphilis: Benzathine Penicillin 2.4 million UI single-dose IM, once or each concecutive week for three weeks depending on patient history/RPR</li> <li>Syphilis in pregnant women: 2.4 million IU IM each week for 3 weeks</li> <li>Chancroid: Azithromycin 1g PO single dose OR Ceftriaxone 250mg single dose IM OR Ciprofloxacin 500mg bid for 3 days</li> <li>Chancroid in pregnant/lactating women: Erythromycin 500mg PO QID for 15 days</li> <li>Lymphogranuloma venerum: Doxycycline 100mg PO daily for 21 days OR Erythromycin 500mg PO QID for 21 days OR Azithromycin 1g PO each week for 3 weeks</li> <li>Gonorrhea: Ceftriaxone 500mg IM single dose</li> <li>Chlamydia: Azithromycin 1g PO single dose or Doxycycline 100mg PO bid for 7 days.</li> <li>Trichomonas vaginalis: Metronidazole 2g PO single dose</li> </ol>
	<ul> <li>11. Candida albicans: Fluconazole 150mg PO single dose OR Clotrimazole ovules 100mg intravaginal for 7 days</li> <li>12. Bacterial vaginosis: Metronidazole 2g PO single dose</li> </ul>
General and Tropical Medicine	12. Dacterial vaginosis. Metroindazoie 2g FO siligie dose
	<ol> <li>Cardiovascular system: Symptoms associated with myocarditis, endocarditis, pericarditis with clinical suspicion of:</li> <li>1.1 Mild leptospirosis: Doxycycline 100mg PO bid for 7 days OR Azithromycin 500mg PO each day for 3 days</li> <li>1.2 <i>Trypanosoma cruzi</i>: Benznidazole 5-7mg/kg/day PO divided in two doses: bid for 60 days</li> <li>1.3 <i>Taenia solium</i>: Praziquantel 10mg/kg PO single dose</li> <li>1.4 <i>Ascaris lumbricoides</i>: 400mg PO single dose</li> </ol>
	<ul> <li>1.5 Strongyloides stercolaris: Ivermectin 200 μg/kg/day PO for 1- 2 days</li> <li>1.6 Paragonimus westermanii: Praziquantel 25mg/kg PO tid for 2 days</li> </ul>

> 1.7 Mansonella perstans: Doxycycline 200mg PO each day or 100mg PO bid for 6 weeks 2. Congestive Heart Failure symptoms that might be due to: 2.1 Schistosoma mansonii: Praziquantel 40mg/kg PO single dose 3. Loeffler Syndrome that might be due to: 3.1 Ascaris lumbricoides: Albendazole 400mg PO single Dose 3.2 Strongyloides stercolaris: Ivermectin 200 µg/kg/day PO for 1-2 days 3.3 Ancyslostoma duodenale: Albendazole 400mg PO for 1-3 days 3.4 Necator americanus: Albendazole 400mg PO for 1-3 days 4. Dyspnea or Pneumonia suspicion due to: 4.1 Streptococcus pneumoniae: With recent use of antibiotics and comorbidities: Amoxicillin-Clavulanate 875/125mg-1 tablet PO bid + Clarithromycin 500mg PO bid for 7 days OR Azithromycin 500mg PO in the first dose and then 250mg PO each day for 4 days With recent use of antibiotics and no comorbidities: Amoxicillin 1g PO bid for 7 days -No recent use of antibiotics: Clarithromycin 500mg PO bid for 7 days or Azithromycin 500mg PO in the first dose and then 250mg PO each day for 4 days. 4.2 Mycoplasma pneumoniae / Chlamydia pneumoniae / Chlamydia psittaci: Doxycycline 100mg PO bid for 7 days 4.3 Haemophilus influenzae: Amoxicillin/Clavulanate 875/125mg tab one tablet PO bid for 7 days. 4.4 Legionellosis: Levofloxacin 750mg PO each day for 10 days 4.5 Coccidioidomycosis: Fluconazole 400mg PO each day for 3-12 months 4.6 Blastomycosis: Itraconazole 200mg PO tid for 3 days and then each day for 6-12 months 4.7 Schistosoma mansonii: Praziquantel 40mg/kg PO single dose 4.8 Filariasis: Doxycycline 100mg PO each day for 6-8 weeks 5. Gastrointestinal symptoms- Hepato-splenomegaly by clinical diagnosis or suspicion of the following etiologies: 5.1 Schistosoma mansonii / japonicum: Praziquantel 40mg/kg-60mg/kg PO single dose (without previous treatment, dependent on country of origin) Suspiacian of acute toxemic shistosomiasis: short corse high-dose prednisone + 40mg/kg-60mg/kg Praziguantel PO in single dose, repeat Praziguantel in 4-6 weeks. 5.2 Toxocariosis: Albendazole 400mg PO bid for 5 days + Prednisone (optional) 60mg each day for 5 days Jaundice (pre-hepatic-post) by clinical diagnosis or suspicion of the following etiologies: 5.3 Bartonella bacilliformis: Doxycycline 100mg PO each day for 6-8 weeks 5.4 Coxiella burnetti: Doxycycline 100mg PO each day for 2 weeks 5.5 Chlamydia psittaci: Doxycycline 100mg PO each day for 7 days 5.6 Salmonella typhi: Levofloxacin 750mg PO each day for 7 days

	5.7 <i>Ascaris lumbricoides</i> : Albendazole 400mg PO single dose (may also be related to malabsorption syndrome)
	5.8 Cryptosporidium parvum/hominis: Nitazoxanide 500mg PO bid for 3 days
	5.9 Giardia lamblia: Tinidazole 2g PO single dose (may also be related to malabsorption
	syndrome)
	5.10 <i>Strongyloides stercolaris</i> : Ivermectin 200µg/kg/day for 1-2 days
	5.11 Trichinellosis: Albendazole 400mg bid for 8-14 days + Prednisone 60mg PO each
	day
	6. Cutaneous- by papule / macule (vascular or not painful)
	6.1 Bartonella henselae/bacilliformis: Doxycycline 100mg PO each day for 7 days
	6.2 Human Papillomavirus: Podofilox gel or solution at 0.5% - apply tid for 30 days
	6.3 Molluscum contagiosum: Amphotericin B 0.6mg/kg/day PO for 2 weeks OR
	Itraconazole 400mg/day PO for 10 weeks and then 200mg/day PO till the CD4 count in
	HIV patients is >100cells / $\mu$ L for >6 months responding to RVT
	By papule/macule (painful)
	6.4 Dermatobia hominis / Cordylobia anthropophaga / Tunga penetrans: Petroleum jelly or
	an occlusive agent so when the larva moves, a manual extraction is done.
	By papule/macule that causes itch
	6.5 Schistosoma spp: Praziquantel 40mg/kg single dose PO
	6.6 Pediculus humanus corporis/capitis: Ivermectin 12mg PO each day for 14 days
	6.7 <i>Sarcoptes scabiei</i> : Permethrin cream 5% apply on skin for 8-14 hours and repeat in 1-2
	weeks
	Vesicles
	6.8 Herpes simplex virus 1 and 2 : Acyclovir 400mg PO tid for 7-10 days
	6.9 Sporotrichosis: Itraconazole 200mg PO each day for 2-4 weeks
	6.10 <i>Rickettsia akari/prowazekii/typhi /</i> Leptospirosis: Doxycycline100mg PO bid for 7
	days
	6.11 <i>Borrelia burgdorferi</i> : Doxycycline 100mg PO bid for 2 weeks
	Morbilliform exantem
	6.12 <i>Mycoplasma pneumoniae</i> : Doxycycline 100mg PO bid for 7 days
	6.13 <i>Ehrlichia chafeensis / Anaplasma phagocytophilum</i> 100mg PO bid for 2 weeks
	6.14 <i>Histoplasma capsulatum</i> : Itraconazole 200mg TID for 3 days, then 200mg bid for
	12 months
	6.15 <i>Coccidioides posadasii</i> : Fluconazole 400mg PO each day for 3-12months
	6.16 Sporothrix spp.: Itraconazole 200mg PO each day for 2-4 weeks
	<ul><li>6.17 Actinomycetoma: Itraconazole 200mg PO each day for 2-4 weeks</li><li>6.18 Chromoblastomycosis (<i>Fonsacaea pedrosoi</i>): Itraconazole 300mg PO each day for</li></ul>
	3-9 months
Nutrition	

Mild-moderate acute malnutrition in:
-Children from 0 to 6 months
-Children from 6 months to 5 years
-Children 6-17 years old
-18 years or above: Men and women
-Pregnant women

# Supplementary table A: Causes for referral to primary, secondary and tertiary centers.

Study component	Motive for Referral						
Quantitative Questionnair e							
	Ongoing distress						
Mental health							
	Ongoing distress, psychosis and / or risk of self or hetero-aggressive outburst						
Sexual and Reproductive Health							
	13. Reported violence: by time since violence occurred and if PEP is possible and support is needed						
	14. HIV positive: refer if had 6 months or more of continuous treatment prior to study and would like to continue treatment; otherwise receive prophylaxis for AIDS-related opportunistic infections.						
	15. Syphilis positive- If congenital syphilis is suspected, if the patient is a kid with <30kg of weight or lactating.						
	16. Pelvic inflammatory disease: Severity symptoms such as fever, nausea, severe abdominal pain; if associated with a pelvic abscess or pregnancy						
Pregnancy	<ul> <li>5. Early pregnancy bleeding (first trimester):</li> <li>5.1 Threatened abortion</li> <li>5.2 Ectopic pregnancy</li> <li>5.3 Gestational trophoblastic disease</li> <li>5.4 Pregnancy loss</li> <li>6. Second and third trimester bleeding:</li> <li>6.1 Placenta previa</li> <li>6.2 Placental abruption</li> <li>6.3 Pregnancy loss</li> <li>7. Complications in the duration of pregnancy</li> <li>7.1 Pre-term labour</li> <li>7.2 Pre-term membrane rupture</li> <li>7.3 Post-term pregnancy</li> <li>8. Hypertensive disorders in pregnancy</li> <li>9. Post-partum hemorrhage</li> <li>10. Infections during pregnancy</li> <li>10.1 Hepatitis B</li> <li>10.2 Toxoplasmosis</li> <li>10.3 Tuberculosis</li> <li>10.4 Genital herpes</li> <li>10.5 HIV</li> <li>10.6 Sepsis</li> </ul>						

	<ul><li>11. Mental health disturbances associated to pregnancy:</li><li>11.1 Postpartum depression</li><li>11.2 Perinatal dwelling</li></ul>				
General and Tropical Medicine					
	7. Neurological symptoms independent of etiology: meningism signs, polyneuropathy, acute flaccid paralysis, convulsions, autonomic symptoms.				
	<ol> <li>8. Cardiovascular system: Symptoms associated to myocarditis, endocarditis, pericarditis with clinical suspicion of:</li> <li>8.1 Diphtheria</li> </ol>				
	<ul> <li>8.2 Neisseria meningitidis</li> <li>8.3 Coxiella burnetii</li> <li>8.4 Mycobacterium tuberculosis</li> <li>8.5 Source leptospirosis</li> </ul>				
	<ul><li>8.5 Severe leptospirosis</li><li>8.6 West Nile river fever</li><li>8.7 Yellow fever</li><li>8.8 HIV</li></ul>				
	<ul> <li>9. Congestive Heart Failure symptoms that might be due to:</li> <li>9.1 Acute rheumatic fever</li> <li>9.2 Acute Chagas disease</li> <li>9.3 Wet Beriberi</li> <li>9.4 Anemia</li> </ul>				
	10. Stroke: by symptoms or clinical suspicion of:         10.1       HIV         10.2       Toxoplasma gondii         10.3       Syphilis         10.4       Echinococcosis				
	<ul> <li>11. Cough by symptoms or clinical suspicion of:</li> <li>11.1 Brucellosis</li> <li>11.2 Mycobacterium tuberculosis</li> <li>11.3 Coxiella burnetii</li> <li>11.4 Bordetella pertussis</li> <li>11.5 Lassa fever</li> <li>11.6 Hantavirus</li> <li>11.7 COVID-19</li> </ul>				
	<ul> <li>12. Pneumonia clinically diagnosed or suspicion of the following etiologies:</li> <li>12.1 Aspergillosis</li> <li>12.2 Histoplasmosis</li> <li>12.3 Burkholderia pseudomallei</li> <li>12.4 Influenza</li> <li>12.5 Pneumocystis jirovecii</li> </ul>				

	13. Hemoptysis- Clinical diagnose or suspicion of the following etiologies:					
	13.1 Yersinia pestis					
	13.2 Mycobacterium tuberculosis					
	13.3 Mycobacterium abscessus					
	13.4 Staphylococcus aureus					
	13.5 Meliodosis/ Burkholderia pseudomallei					
	13.6 Paragonimus westermanii					
	14. Pneumonia by vaccine-prevented etiologies					
	15. Hepato-splenomegaly- with high suspicion of the following etiologies:					
	15.1 Mycobacterium tuberculosis					
	15.2 Hepatitis virus A,B,C,D,E					
	15.3 Malaria					
	15.4 Visceral Leishmania					
	15.5 Congenital Trypanosoma cruzi					
	15.6 Histoplasma capsulatum					
	16. Ictericia- with suspicion or diagnosis of the following etiologies:					
	16.1 Schistosoma japonicum / mansoni					
	16.2 Malaria					
	16.3 Babesiosis					
	16.4 Hepatitis virus A,B,C,D, E					
	16.5 Dengue virus					
	16.6 Yellow fever					
	16.7 Rift Valley fever					
	16.8 Coxiella burnetii					
	16.9 Brucellosis					
	16.10 Mycobacterium tuberculosis					
	17. Severe dehydration secondary to diarrhea or dysentery					
	<ul><li>18. Cutaneous affectations secondary to:</li><li>18.1 Mycobacterium leprae</li></ul>					
	· 1					
	18.3 Mycobacterium abscessus					
	18.4 Mycobacterium ulcerans					
	18.5 Corynebacterium diphtheria					
	18.6 Leishmaniasis					
	18.7 Neisseria meningitidis					
	18.8 Ebola/Marburg					
	18.9 Dengue virus					
	18.10 Chikungunya					
	18.11 Rubeola					
	18.12 HIV/Acute Retroviral Symptoms					
	18.13 Measles					
	18.14 West Nile Virus					
Nutrition						
	Severe acute malnutrition in:					
	-Children from 0 to 6 months -Children from 6 months to 5 years					
	-Children 6-17 years old					
	-18 years or above: Men and women					
	-Pregnant women					

## Supplementary Material B: Distress protocol

The distress protocol will be filled out by the researcher or field assistant involved in the identification of the distress. The following questions will be answered, and if if the response is yes on any, the situation will be reported to the principal investigator.

## Questions to ask of the participant in a state of distress (circle one)

- Did the participant show signs of distress related to a part of the study (partner violence, sexual violence, any other kind of violence or another topic in the study?) **Yes / No**
- Did the participant have to abandon the study due to the distress? Yes / No
- Did the participant report a situation of violence (intimate partner or another)? Yes / No
- Did or does the participant presenta acute psychosis and or an elevated risk of self o hetero agression? **Yes / No**

If the participant answered yes to any of these questions, please find the PI or the coinvestigator in charge.

## To be explained to the participant: "we would like to support all participant who present with distress of any kind. Do you have any questions about the study?"

## Directions after a "yes" was received to the answers above

1. Take the participant to a safe place and ask how they feel

2. Listen to the participant. If they share something, listen with empathy to whatever they want to share.

3. Invite the participant to meet again with you at a specific time, within a couple hours.

4. If the participant comes to the meeting, ask how they are feeling.

5. If the participant is still in a distressed state, or a psychotic break or a situation of increased risk of self or retrogression, they should be taken for an evaluation with the study psychiatrist, who will evaluate if the individual needs further assistance through a referral.

# Supplementary material C:

## Management of individuals who report sexual violence

If sexual violence has been reported, Ministry of Health authorities will be contacted discreetly; the decisión to contact the authorities will be made by the PI or another co-investigator who is in charge.

The table below indicates where and with what urgency the reference to the Ministry of Health or should be made. These are based on the Ministry of Health (MOH) procedure for sexual violence, rape, incest, and a previously published protocol for children who report violence (26).

The participant reports	urgency of the referral	Reported incident	Referral to	Time to undertake the response and referral
Level 1: Forced sexual intercourse, or severe sexual violence in the last 72 hours	Urgent	In the last 72 hours, you have been forced to have sex	Referral and accompaniment to MOH personnel	Within 6 hours of the incident report.
Level 2: Severe sexual violence between 3 to 14 days, and minor sexual violence, or if it is more than a week, but the person was in Panamanian territory.	Less urgent, but with notification	Between 3-14 days, the violation occurred. Or, at any time, some less severe act: someone touched their genitals, breasts, or buttocks; forced to touch the genitals, breasts, or buttocks of another person; Other disclosures that do not meet the same criteria for urgency or seriousness as for the urgent need for urgent medical care.	Referral and accompaniment to MOH personnel	As soon as possible (within 24 hours)
Level 3: Severe sexual violence in 8 days until the last year, but no incident within Panamanian territory	Without notification, if it occurred outside of Panamanian territory, consult with mental health.	As in level 2, but 8 days until the last year (outside of Panamanian territory).	Go to a mental health consultation, psychology and / or psychiatry staff	When detected
No reports of any specific violent act, but the participant indicates that they would like additional support.	Referral to study mental health staff, volunteer		Go to a mental health consultation, psychology and / or psychiatry staff	Within 6 hours of having been detected